You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia

  • Technology appraisal guidance
  • Reference number: TA1049
  • Published:  26 March 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Resource impact
  2. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

  • Resource impact template (Excel 986 KB)

    Published:
    26 March 2025
  • Resource impact summary report

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top